Genetic, vascular, and amyloid determinants of cerebral blood flow in a preclinical population


Genetic, vascular, and amyloid determinants of cerebral blood flow in a preclinical population

Padrela, B. E.; Lorenzini, L.; Collij, L. E.; Vállez García, D.; Coomans, E.; Ingala, S.; Tomassen, J.; Deckers, Q.; Shekari, M.; de Geus, E. J. C.; van de Giessen, E.; Ten Kate, M.; Jelle Visser, P.; Barkhof, F.; Petr, J.; Den Braber, A.; Mutsaerts, H. J. M. M.

Abstract

Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascular and cerebrovascular dysfunction, and amyloid-β burden. Whereas cerebral blood flow (CBF) has been studied as a potential early biomarker of cognitive decline, its normal variability in healthy elderly is less known. In this study, we investigated the contribution of genetic, vascular, and amyloid-β components of CBF in a cognitively unimpaired (CU) population of monozygotic older twins. We included 134 participants who underwent arterial spin labeling (ASL) MRI and [18F]flutemetamol amyloid-PET imaging at baseline and after a four-year follow-up. General estimating equations were used to investigate the associations of amyloid burden and white matter hyperintensities with CBF. We showed that, in CU individuals, CBF: 1) has a genetic component, as within-pair similarities in CBF values were moderate and significant (ICC>0.40); 2) is negatively associated with cerebrovascular damage; and 3) is positively associated with the interaction between cardiovascular risk scores and early amyloid-β burden, which may reflect a vascular compensatory response of CBF to early amyloid-β accumulation. These findings encourage future studies to account for multiple interactions with CBF in disease trajectory analyses.

Beteiligte Forschungsanlagen

  • PET-Zentrum

Permalink: https://www.hzdr.de/publications/Publ-36407